Skip to main content
PMC home page
Frontiers in Cardiovascular Medicine logoLink to Frontiers in Cardiovascular Medicine
. 2023 Jan 13;9:1059420. doi: 10.3389/fcvm.2022.1059420

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction

Pei Yang 1,2,†, Xiaokang Li 3,†, Lijin Wang 3,†, Xinlei Wu 3, Chiyao Wang 3,*, Tian Li 4,*, Haiyan Wang 1,*
PMCID: PMC9880431  PMID: 36712243

Abstract

Introduction

In 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from cardiovascular causes more effectively than enalapril (an ACEI) in heart failure patients with reduced ejection fraction (HFrEF). Similarly, the PARADIGM-HF trial (Comparison of Sacubitril-Valsartan vs. Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode) came to similar conclusions and extended the PARADIGM-HF trial results in 2019. Since then, numerous new studies have provided further insight in HFrEF, sacubitril/valsartan can reduce N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, increase left ventricular ejection fraction (LVEF), reverse ventricular remodeling, and reduce other non-fatal manifestations of clinical deterioration as compared to ACEI/ARB. However, few trials have compared the effects of these drugs in patients shortly after AMI. Therefore, it is necessary to further explore the clinical efficacy and safety of sacubitril/valsartan vs. valsartan in patients with AMI.

Methods

We conducted an open-label, prospective, randomized controlled trial to determine the superiority in ameliorating ventricular remodeling and preventing of heart failure in patients with AMI after percutaneous coronary intervention (PCI), 148 patients were randomly assigned (85 to sacubitril/valsartan and 63 to valsartan).

Results

LAV, LVDV, and LVSV were all decreased in the sacubitril/valsartan group when compared with before treatment, but there was no difference between the sacubitril/valsartan group and the valsartan group. In addition, compared with before treatment in the sacubitril/valsartan group, the heart global work index (GWI) and the global work efficiency (GWE) increased, while the heart global wasted work (GWW) decreased. Patients in the sacubitril/valsartan group have similar MACE and adverse side effects to those in the valsartan group.

Conclusion

Sacubitril/valsartan has the same performance as valsartan in inhibiting ventricular remodeling and preventing heart failure after PCI in patients with AMI, and its clinical application is safe. It provides a clinical foundation for the application of sacubitril/valsartan in patients with AMI.

Keywords: sacubitril, valsartan, acute myocardial infarction, coronary intervention, retrospective study

1. Introduction

The high risk of sudden death and high disability rate of acute myocardial infarction (AMI) posed a serious threat to people’s physical and mental health (1, 2). The main reason for this is coronary atherosclerosis, after which multiple triggers lead to the rupture of unstable plaques and thrombosis. Such as increased sympathetic excitability, enhanced body stress response, a high-fat diet, and emotional agitation. Fatal complications often occur in the early stage of AMI, such as acute heart failure, ventricular aneurysms, and cardiac rupture (3). Prompt initiation of vascular dredging in patients with AMI can save the dying myocardium and prevent the expansion of the infarct. In addition, administration of ACEI or ARB can prevent and reverse cardiac remodeling, reduce the risk of cardiovascular death or heart failure hospitalization, reduce the long-term risk of death, and improve the quality of life of patients (4–7).

Sacubitril/valsartan, as an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown better effects than ACEI or ARB in many clinical trials among patients with chronic heart failure with reduced ejection fraction (8–12). However, whether there is a long-term benefit of sacubitril/valsartan in patients with acute myocardial infarction after PCI is still controversial (13–15). Several studies have shown that early application of sacubitril/valsartan is effective and safe in inhibiting ventricular remodeling in animal models of myocardial infarction (16–20). Therefore, it is also worthy of investigation and exploration to determine whether this efficacy and safety can continue to be prominent in clinical practice. Consequently, we conducted an open-label, prospective, randomized controlled trial to investigate the effects of sacubitril/valsartan in patients with AMI after PCI.

2. Methods

2.1. Study design and oversight

A total of 175 patients with AMI in the Second Affiliated Hospital of Air Force Military Medical University were recruited between November 2019 and February 2021, and finally, 148 patients were randomly assigned (85 to sacubitril/valsartan and 63 to valsartan). Follow-up and data analysis were carried out 1, 3, and 6 months after PCI. The design of this trial has been approved by the Ethics Committee of the Second Affiliated Hospital of Air Force Military Medical University (No. 201909-06) and registered in the China Clinical Trials Registration Center (ChiCTR2000041383).

2.1.1. Inclusion criteria

(1) Individuals diagnosed with AMI, Killip I∼III grade. (2) Individuals between the ages of 20 and 80 years. (3) Individuals willing to provide written informed consent and who can comply with study procedures and follow-up.

2.1.2. Exclusion criteria

(1) Individuals diagnosed with AMI, Killip IV grade, not eligible for PCI. (2) Individuals with severe hepatic insufficiency (Child-Pugh C grade) or severe renal insufficiency [eGFR < 30ml/(min⋅1.73m2)]. (3) Individuals with symptomatic hypotension (systolic blood pressure ≤ 90 mmHg). (4) Pregnant and lactating individuals. (5) Individual cognitive impairment. (6) Individuals have other serious illness or life expectancy < 6 months (21).

2.2. Therapeutic regimen

After the patients were admitted to the hospital, the basic information and risk factors of coronary heart disease were recorded through the interrogation. The type of myocardial infarction was determined according to the electrocardiogram (ECG), ultrasound, cardiac function, and biochemical examination. Coronary artery lesions were illustrated by the post-PCI records (the operation was performed by the attending physician or assistant director physician).

In addition to basic therapy, eligible patients were randomly assigned to receive treatment, in a double-blind manner, with either sacubitril/valsartan (100 mg twice daily) or valsartan (80 mg once a day). It needs to stop the drug for at least 36 h to avoid the occurrence of angioedema if they have taken ACEI/ARB drugs in the past. Based on the clinical manifestations of the patient and the occurrence of adverse reactions, it is necessary to determine whether to adjust the dose of the drug.

2.3. Evaluation

The primary outcome was the change from baseline to 6 months in LVEF or ultrasound indicators of cardiac resynchronization. Secondary outcomes, measured as the change from baseline to 6 months, were NT-proBNP, 6-minute walk distance (6MWD), systolic blood pressure (SBP), and diastolic blood pressure (DBP) (15). Safety parameters were assessed during the whole study based on MACE and adverse side effects. MACE included deaths from coronary heart disease, myocardial infarction, heart failure, severe arrhythmia, and recurrent angina pectoris. Adverse side effects included symptomatic hypotension (symptoms of hypotension with SBP ≤ 90 mmHg), angioedema, deterioration of renal function (serum creatinine ≥ 221 umol/L), and hyperkalemia (K+ ≥ 5.5 mmol/L). Trial visits were scheduled at 1, 3, and 6 months. During each visit, patients underwent comprehensive examinations, clinical safety assessments, and medication compliance analysis.

2.4. Statistical analysis

All statistical analyses were performed using the IBM SPSS 25.0 statistical software (IBM Inc., Chicago, IL, USA). After the Kolmogorov–Smirnov normality test, the measurement data that conformed to the normal distribution were expressed as the mean ± standard deviation. The comparison between the two groups was performed using the independent sample t-test. The comparison between before and after treatment was performed using the paired sample t-test. The measurement data that did not conform to normal distribution were expressed as quartile spacing. The Mann–Whitney U test was used for comparison between two groups, and the Wilcoxon signed-rank test was used for comparison before and after treatment. The count data were expressed as numbers and analyzed by Pearson’s Chi-squared test. Fisher’s exact test was used if the expected value was less than 5. Multiple linear regression models were used to study the effects of multiple variables. P-value < 0.05 was considered statistically significant (22).

3. Results

3.1. Baseline characteristics

A total of 175 subjects were initially recruited. Among these patients, we excluded 12 patients with severe heart failure of Killip IV grade, 3 patients with severe renal insufficiency, 5 patients with symptomatic hypotension, 2 patients with sudden postoperative death, and 5 patients who refused to sign informed consent were excluded. Eventually, a total of 148 patients were included in the trial (Figure 1). These samples were randomly divided into the sacubitril/valsartan group (T group) and the valsartan group (C group).

FIGURE 1.

FIGURE 1

Open in a new tab

Flow chart of the research scheme showing the design of the study and detailed study selection process. Group T, sacubitril/valsartan group; Group C, valsartan group; AMI, acute myocardial infarction.

The baseline characteristics of the patients were shown in Table 1. After random assignment, two groups were well-balanced in terms of demographic and clinical characteristics.

TABLE 1.

The baseline characteristics of the patients.

Variables T group (n = 85) C group (n = 63)
Age (years) 59.07 ± 11.532 59.92 ± 12.019
Male 75 (88.2) 57 (90.5)
BMI (kg/m2) 22.96 ± 2.195 23.00 ± 2.540
Hypertension 44 (51.8) 36 (57.1)
Diabetes 18 (21.2) 17 (27)
Dyslipidaemia 16 (18.8) 10 (15.9)
Smoking 46 (54.1) 32 (50.8)
Family history 6 (7.1) 6 (5.1)
Myocardial infarction 7 (8.2) 3 (4.8)
Ischemic stroke 7 (8.2) 7 (11.1)
Valvular disease 1 (1.2) 1 (0.9)
Atrial fibrillation 3 (3.5) 1 (1.6)
STEMI 51 (60.0) 39 (61.9)
Culprit vessel
LAD 56 (65.9) 39 (61.9)
LCX 4 (4.7) 5 (7.9)
RCA 25 (29.4) 19 (30.2)
Killip classification
I 67 (78.8) 54 (85.7)
II 13 (15.3) 7 (11.1)
III 5 (5.9) 2 (3.2)
Lesion artery number
Single-vessel 39 (45.9) 26 (41.3)
Double-vessel 29 (34.1) 20 (31.7)
Triple-vessel 17 (20.0) 17 (27.0)
CTO 6 (7.1) 3 (4.8)
Laboratory analysis
CK-MB (ng/mL) 21.60 (3.38, 97.0) 27.10 (4.07, 94.2)
cTnI (ng/ml) 4.21 (1.04, 27.2) 3.04 (0.58, 20.7)
NT-proBNP (pg/ml) 869 (378, 2130) 588 (202, 1364)
eGFR (ml/min/1.73m2) 94.80 ± 20.132 95.72 ± 15.510
Creatinine (μmol/L) 71.98 ± 22.750 70.02 ± 17.917
Drugs at discharge
Aspirin 64 (75.3) 54 (85.7)
Clopidogrel 81 (95.3) 61 (96.8)
Ticagrelor 4 (4.7) 2 (3.2)
Statins 85 (100) 63 (100)
β receptor blocker 82 (96.5) 62 (98.4)
Diuretics
Furosemide 10 (11.8) 6 (9.5)
Spironolactone 17 (20.0) 11 (17.5)
Both 9 (10.6) 5 (7.9)
Open in a new tab

BMI, body mass index; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; CTO, chronic total occlusion; STEMI, st-segment elevation myocardial infarction; CK-MB, creatine kinase myocardial band; cTnI, cardiac troponin I; NT-proBNP, N-terminal pro-brain natriuretic peptide; eGFR, estimate glomerular filtration rate.

3.2. Comparison of echocardiographic results

All patients took the heart echocardiographic test and valued the left atrium volume (LAV), left ventricular end-diastolic volume (LVDV), and left ventricular end-systolic volume (LVSV) before and after the treatment. We found that LAV, LVDV, and LVSV in T group were significantly decreased (LAV, baseline 59.73 ± 19.01, 6 m 53.33 ± 16.94, P < 0.001; LVDV, baseline 117.47 ± 25.43, 6 m 113.33 ± 22.32, P < 0.001; LVSV, baseline 56.60 ± 17.49, 6 m 49.90 ± 19.36, P < 0.001) at 6 months after the treatment (Table 2 and Figure 2). There was no significant difference between the T group and the C group (LAV, T group 53.33 ± 16.94, C group 65.04 ± 19.95, P = 0.102; LVDV, T group 113.33 ± 22.32, C group 116.85 ± 27.17, P = 0.875; LVSV, T group 49.90 ± 19.36, C group 51.27 ± 18.70, P = 0.645) (Table 2).

TABLE 2.

Primary and secondary end points changes between the two groups from the baseline to follow-up.

Variables Baseline Follow-up (3 m) Follow-up (6 m)
T group (n = 85) C group (n = 63) P-value T group (n = 71) C group (n = 47) P-value P-value* T group (n = 21) C group (n = 26) P-value P-value*
LAV 59.73 ± 19.01 58.95 ± 12.94 0.780 60.76 ± 18.21 62.64 ± 21.06 0.557 0.357 53.33 ± 16.94 65.04 ± 19.95 0.102 <0.001
LVDV 117.47 ± 25.43 111.98 ± 21.60 0.169 123.39 ± 30.62 114.36 ± 29.48 0.682 0.154 113.33 ± 22.32 116.85 ± 27.17 0.875 <0.001
LVSV 56.60 ± 17.49 52.56 ± 13.98 0.120 60.70 ± 24.85 51.09 ± 18.86 0.240 0.201 49.90 ± 19.36 51.27 ± 18.70 0.645 <0.001
LVEF 51.93 ± 9.11 52.25 ± 7.38 0.817 51.55 ± 9.47 54.92 ± 8.36 0.147 0.963 55.19 ± 7.94 55.73 ± 8.33 0.480 0.230
6MWD 330 ± 49.4 338 ± 63.2 0.323 521 ± 63.7 487 ± 54.3 0.001 <0.001 546 ± 44.4 525 ± 15.2 0.012 <0.001
SBP 123.76 ± 22.06 122.70 ± 18.86 0.758 113.78 ± 12.89 112.52 ± 9.06 0.950 <0.001 109.49 ± 9.80 109.98 ± 9.60* 0.626 <0.001
DBP 78.20 ± 14.08 77.68 ± 13.16 0.821 74.40 ± 11.60 71.08 ± 8.54 0.175 0.003 72.58 ± 9.77 70.81 ± 8.11 0.352 <0.001
NT-proBNP 869 (378, 2130) 588 (203, 1364) 0.146 324 (158, 1210) 327 (195, 539) 0.335 0.012 338 (166, 643) 169 (105, 369) 0.254 0.002
Open in a new tab

LAV, left atrium volume; LVDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; 6MWD, 6-minute walk distance; SBP, systolic blood pressure; DBP, diastolic blood pressure.

P-value: difference between groups at a single time point; P-value*: difference within T group over time.

FIGURE 2.

FIGURE 2

Open in a new tab

Primary and secondary end points changes between the two groups from the baseline to follow-up. (A) Difference in LAV between groups over time. (B) Difference in LVDV between groups over time. (C) Difference in LVSV between groups over time. (D) Difference in LVEF between groups over time. (E) Difference in 6MWD between groups over time. (F) Difference in SBP between groups over time. (G) Difference in DBP between groups over time. (H) Difference in NT-proBNP between groups over time.

3.3. Comparison of vital signs biochemical index

Compared with that before treatment, the index of 6MWD, SBP, DBP, NT-proBNP improved in both T and C group after 3 months and 6 months of treatment (P < 0.05). When we compared the T and C groups, SBP, DBP, and NT-proBNP did not show any significant differences. However, the 6MWD was significantly higher in T group than that in C group (P < 0.05) (Table 2 and Figure 2).

3.4. Cardiac resynchronization parameters

Compared with before treatment, the indexes of cardiac work (GWI, GWW, and GWE) in the sacubitril/valsartan group 6 months after the treatment were significantly improved (GWI: baseline, 1094.28 ± 428.53; 6 m, 1421.00 ± 421.23, P = 0.011; GWW: baseline, 265.16 ± 151.18; 6 m, 162.77 ± 99.99, P = 0.005; GWE: baseline, 83.24 ± 6.89; 6 m, 89.65 ± 5.85; P = 0.002). The left ventricular diastolic and systolic functions (GLS-AVG, LVDT, and VTIMV) were also significantly improved (P < 0.05) (Table 3 and Figure 3). However, there was no statistical significance on these indexes between the two groups (P > 0.05) (Table 3).

TABLE 3.

Tissue synchronization imaging changes between the two groups from the baseline to follow-up.

Variables Baseline Follow-up (3 m) Follow-up (6 m)
T group (n = 25) C group (n = 19) P-value T group (n = 18) C group (n = 7) P-value P-value* T group (n = 17) C group (n = 13) P-value P-value*
GWI 1094.28 ± 428.53 1234.21 ± 503.38 0.325 1415.11 ± 453.97 1717.29 ± 354.26 0.132 0.001 1421.00 ± 421.23 1617.39 ± 471.17 0.268 0.011
GCW 1491.80 ± 476.32 1487.00 ± 487.49 0.974 1697.39 ± 562.23 2039.43 ± 415.10 0.056 0.136 1674.65 ± 434.06 1868.23 ± 458.92 0.091 0.165
GWW 265.16 ± 151.18 158.79 ± 119.83 0.016 190.72 ± 104.08 156.14 ± 108.31 0.489 0.099 162.77 ± 99.99 155.23 ± 92.70 0.112 0.005
GWE (%) 83.24 ± 6.89 88.11 ± 7.53 0.031 88.06 ± 5.13 91.57 ± 4.08 0.943 0.023 89.65 ± 5.85 90.85 ± 4.96 0.340 0.002
LASr 0.20 ± 0.08 0.262 ± 0.108 0.039 0.25 ± 0.09 0.26 ± 0.10 0.463 0.012 0.25 ± 0.09 0.26 ± 0.08 0.203 0.121
LAScd −0.09 ± 0.07 −0.13 ± 0.06 0.092 −1.44 ± 5.63 −0.126 ± 0.05 0.541 0.322 −0.11 ± 0.06 −0.13 ± 0.05 0.537 0.141
LASct −0.11 ± 0.06 −0.14 ± 0.07 0.129 −0.11 ± 0.09 −0.13 ± 0.06 0.989 0.930 −0.137 ± 0.049 −0.12 ± 0.06 0.136 0.307
SV 55.68 ± 16.61 48.90 ± 12.71 0.146 56.06 ± 11.18 51.429 ± 9.13 0.520 0.118 54.06 ± 10.77 53.15 ± 11.99 0.714 0.566
CO 5.65 ± 8.10 3.705 ± 0.670 0.303 5.28 ± 7.22 3.30 ± 0.47 0.672 0.219 5.85 ± 9.86 3.332 ± 0.82 0.995 0.922
GLS-AVG 12.21 ± 4.18 13.61 ± 4.22 0.280 14.86 ± 4.01 16.54 ± 2.41 0.186 0.001 15.39 ± 3.58 15.82 ± 2.39 0.595 < 0.001
SPI 0.36 ± 0.09 0.34 ± 0.12 0.604 0.35 ± 0.09 0.35 ± 0.05 0.844 0.643 0.3 ± 0.094 0.35 ± 0.09 0.795 0.183
PSD 71.69 ± 26.73 66.45 ± 23.23 0.500 66.48 ± 21.16 59.24 ± 10.83 0.532 0.791 63.48 ± 21.37 64.53 ± 16.73 0.589 0.271
LVDT 437.92 ± 123.06 472.32 ± 102.52 0.330 532.00 ± 117.92 569.57 ± 107.95 0.670 0.009 502.38 ± 109.30 540.92 ± 116.66 0.912 0.034
RR 789.16 ± 123.14 806.26 ± 110.07 0.636 911.06 ± 119.57 950.86 ± 115.85 0.789 0.003 884.25 ± 121.50 954.62 ± 124.26 0.250 0.030
LVDT/RR 54.36 ± 8.77 58.00 ± 6.94 0.144 57.78 ± 7.24 59.43 ± 4.72 0.335 0.069 56.25 ± 5.86 55.92 ± 6.01 0.077 0.072
VTIMV 21.46 ± 5.37 21.72 ± 4.45 0.869 23.11 ± 4.35 22.17 ± 5.02 0.653 0.287 24.91 ± 5.40 22.56 ± 2.97 0.174 0.028
IVMD 11.60 ± 6.86 14.00 ± 14.67 0.515 8.41 ± 6.91 10.57 ± 5.41 0.760 0.090 8.63 ± 6.25 11.85 ± 12.71 0.748 0.171
SLD 0.0 (−42.0, 21.0) 10.0 (−5.0, 52.5) 0.426 −5.0 (−49.5, 26.8) 0.0 (−47.5, 36.5) 0.739 0.407 −10.0 (−43.0, 52.0) −10.0 (−21.0, 0.0) 0.834 0.365
SPWMD 10.0 (−21.0, 73.0) 0.0 (0.0, 21) 0.933 10.5 (2.5, 57.8) 10.0 (−21.0, 78.5) 0.563 0.371 10.0 (0.0, 84.0) 42.0 (11.0, 83.0) 0.246 0.453
BMD 84.32 ± 50.22 67.90 ± 45.34 0.269 74.67 ± 51.37 96.14 ± 33.11 0.213 0.279 84.59 ± 44.00 83.46 ± 42.83 0.596 0.239
BS 34.72 ± 21.19 26.58 ± 17.94 0.185 30.22 ± 22.29 39.57 ± 15.02 0.120 0.231 36.65 ± 18.05 33.00 ± 17.57 0.697 0.141
aSMD 111.28 ± 48.24 88.11 ± 42.35 0.104 98.78 ± 59.11 115.43 ± 42.29 0.108 0.188 117.12 ± 44.595 112.62 ± 50.00 0.459 0.223
aSS 37.56 ± 18.78 27.90 ± 14.45 0.070 34.50 ± 22.58 40.29 ± 17.05 0.026 0.313 39.12 ± 16.94 37.23 ± 17.22 0.400 0.204
Open in a new tab

GWI, global work index; GWW, global wasted work; GWE, global work efficiency; GLS-AVG, global mean longitudinal strain of left ventricle; LVDT, left ventricular diastolic filling time; RR, R-R interval; VTIMV, velocity time integral of mitral valve; GCW, global constructive work; LASr, left atrial reservoir longitudinal; LAScd, left atrial conduit longitudinal; LASct, left atria contraction longitudinal; SV, stroke volume; CO, cardiac output; SPI, spherical index; PSD, peak strain time dispersion; IVMD, interventricular mechanical delay; SLD, septal lateral delay; SPWMD, septum posterior wall mechanical delay; BMD, basal max delay; BS, basal stdev; aSMD, all seg max delay; aSS, all segments stdev.

P-value: difference between groups at a single time point; P-value*: difference within T group over time.

FIGURE 3.

FIGURE 3

Open in a new tab

Cardiac resynchronization parameters of the two groups before and after the treatment at 3 or 6 months follow-up. (A) Difference in GWI between groups over time. (B) Difference in GWW between groups over time. (C) Difference in GWE between groups over time. (D) Difference in Glps-Avg between groups over time. (E) Difference in LVDT between groups over time. (F) Difference in RR between groups over time.

3.5. Multiple linear regression analyses between GWI and key factors

A multiple linear regression model was used to screen the independent variables affecting GWI. GLS-AVG and LVDT/RR were identified as the main influencing factors (Supplementary Table 1). The levels of GLS-AVG and LVDT/RR were significantly associated with GWI (Figure 4). We also established equations for GWI with GLS-AVG and LVDT/RR to predict the improvement of the overall cardiac work (Supplementary Table 1).

FIGURE 4.

FIGURE 4

Open in a new tab

Multiple linear regression analyses between GWI and key factors. (A,B) The 3D graphs show the relationship between GWI and LVDT/R-R, GIps-Avg. (C) The histogram plot of regression residual standard error. (D) The standard P-P plot of regression residual standard error. (E) Correlation plot of GWI by GIps-Avg. (F) Correlation plot of GWI by LVDT/R-R.

3.6. MACE outcomes and adverse side effects

Hypotension was the most frequent adverse side effect (3.5% in the T group and 3.2% in the C group). And congestive HF was the most frequent MACE (2.4% in the T group and 4.8% in the C group). Comparing these two groups, there was no significant difference in the frequency of MACE and adverse side effects after the treatment (P > 0.05) (Table 4).

TABLE 4.

Major adverse cardiovascular events and adverse side effects between the two groups.

Variables Major adverse cardiovascular events Variables Adverse side effects
T group (n = 85) C group (n = 63) P-value T group (n = 85) C group (n = 63) P-value
Cardiac death, n (%) 1 (1.2) 0.000 1.000 Hypotension, n (%) 3 (3.5) 2 (3.2) 1.000
Myocardial reinfarction, n (%) 1 (1.2) 2 (3.2) 0.575 Angioedema, n (%) 1 (1.2) 0.000 1.000
Congestive HF, n (%) 2 (2.4) 3 (4.8) 0.651 Renal cause, n (%) 1 (1.2) 1 (1.6) 1.000
Malignant arrhythmia, n (%) 0 0 1 Hyperkalemia, n (%) 1 (1.2) 1 (1.6) 1.000
Recurrent angina, n (%) 0 2 (3.2) 0.18 – – – –
All, n (%) 4 (4.7) 7 (11.1) 0.249 All, n (%) 6 (7.1) 4 (6.3) 1.000
Open in a new tab

HF, heart failure.

4. Discussion

Cardiovascular diseases remain the main killer worldwide (23–25). Due to the high risk and high fatality rate of AMI, clinicians are constantly urged to explore how to diagnose, treat, and improve the prognosis as soon as possible to minimize the harm. We know that the total time of myocardial ischemia in patients with acute myocardial infarction determines the size and prognosis of myocardial infarction (26), and ventricular remodeling after myocardial infarction is also affected by a variety of risk factors (27). The risk of ventricular remodeling in patients with anterior wall myocardial infarction was 1.9 times higher than that of infarction at other sites (28). The risk of ventricular remodeling in patients with multi-vessel disease was 1.2 times higher than that in patients with single-vessel disease (29). The severity of chronic total occlusive disease (CTO) and valvular disease is closely related to the degree of cardiac remodeling (30, 31). In theory, early inhibition of ventricular remodeling could delay or prevent the progression of heart failure and reduce the risk of death and rehospitalization. According to the guidelines and consensus, all patients with acute myocardial infarction should use beta blockers or angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists (ARB) as early as possible if there is no contraindication (32, 33).

Based on the study of sacubitril/valsartan in patients with heart failure (34–36), most of the conclusions showed that it was effective in the treatment of hypertension (37), diabetes with chronic renal insufficiency, cardiac insufficiency caused by cardiotoxicity of chemotherapeutic drugs, and functional mitral regurgitation patients (38–42). The purpose of this study is to explore the role of sacubitril/valsartan in cardiac remodeling in patients with myocardial infarction.

This study found that the indexes of cardiac remodeling (LAV, LVDV, and LVSV) improved significantly in the sacubitril/valsartan group after 6 months of treatment, suggesting that sacubitril/valsartan has a significant effect on inhibiting myocardial remodeling in patients with myocardial infarction. This is consistent with the results of a recent meta-analysis confirming that sacubitril/valsartan is effective in improving cardiac remodeling (13, 43, 44). According to previous studies, valsartan was more effective in patients with anterior descending artery disease (45). With more than 60% of patients having anterior descending artery disease, our samples showed fairly high sensitivity to the treatment of valsartan. Our results demonstrated that there was no statistical difference in the indexes of cardiac remodeling between the two groups during the same period, suggesting that sacubitril/valsartan provided equal efficacy to valsartan.

B-type natriuretic peptide (BNP) and N-terminal B-type natriuretic peptide (NT-proBNP) in the family of natriuretic peptides are currently the most widely used biomarkers in the diagnosis and treatment of heart failure, whereas BNP and NT-proBNP detection results are affected by drugs. BNP is the substrate of the enkephalin enzyme, thereby when patients take sacubitril/valsartan, enkephalin inhibitor inhibits enzyme hydrolysis, increasing BNP concentration, while NT-proBNP is not affected by the enkephalin inhibitor. As an important indicator of the prognosis of patients with heart failure, NT-proBNP was also compared between and within groups. Compared with the baseline, the NT-proBNP of both groups decreased significantly after the treatment [T group, baseline 869 (378, 2130), 3 m 324 (158, 1210), 6 m 338 (166, 643), P < 0.05; C group, baseline 588 (203, 1364), 3 m 327 (195, 539), 6 m 169 (105, 369), P < 0.05]. However, there was no statistical difference between the two groups (3 m P = 0.335, 6 m P = 0.254). This result was not consistent with that of previous studies showing that there was a significant difference in NT-proBNP between sacubitril/valsartan and ACEI/ARB drugs at 4 weeks (46, 47). The reason for this result may be due to the fact that this study included patients with acute myocardial infarction, most of them did not have symptoms of severe heart failure with relatively low level of NT-proBNP and large inter-individual differences at the baseline.

Our study found that the GWI and the GWE of the patients after the treatment in the sacubitril/valsartan group increased significantly, while the GWW decreased significantly. It is suggested that sacubitril/valsartan increased the work efficiency of the heart by reducing the ineffective work, indicating that myocardial function is gradually recovering. Meanwhile, during the 6-month follow-up in the valsartan group, the GWI was significantly increased (baseline, 1234.21 ± 503.38; 6 m, 1617.39 ± 471.17; P = 0.001) and the GCW was also significantly increased (baseline, 1487.00 ± 487.49; 6 m, 1868.23 ± 458.92, P = 0.002). However, unlike the T group, the GWW was not significantly decreased (baseline, 158.79 ± 119.83; 6 m, 155.23 ± 92.70; P = 0.165) and the GWE of the heart (baseline, 88.11 ± 7.53; 6 m, 90.85 ± 4.96; P = 0.138) also showed no significant increase. Even though we did not get any significant difference on the indexes of heart work between the two groups after the treatment, the improvement of GWW and GWE in the T group without happening in the C group suggested that the treatment with sacubitril/valsartan could have better efficacy on the improvement of heart work. This could also explain the fact that patients in the T group got higher 6MWD with better cardiac work and increased activity tolerance.

During the study period, the incidences of malignant arrhythmia, renal insufficiency, and hyperkalemia in the test group were 0, 1.2%, and 1.2%, respectively, while those in the control group were 0, 1.6%, and 1.6%, respectively. There was no significant difference between these two groups. Compared with the control group, the incidence of symptomatic hypotension in the test group was higher (3.5%), and the incidence of myocardial infarction and heart failure was lower (1.2 and 1.4%, respectively), but these differences were not significant (P > 0.05). It may be due to the small sample size and relatively short follow-up time in this study. In addition, the use of β-blockers and spironolactone may also interfere with the efficacy of the trial group (22).

5. Conclusion

Overall, this manuscript bears cons. This small sample-size study was performed in a single center. With the extension of follow-up time, there bears loss to follow-up. Additionally, cardiac synchronous ultrasound examination is difficult to perform, and the data lack repetition.

Compared with valsartan, sacubitril/valsartan is also effective in inhibiting ventricular remodeling and preventing heart failure in patients with acute myocardial infarction after PCI, and its clinical application is safe. Our results provide a clinical basis for the application of sacubitril/valsartan in patients with acute myocardial infarction. The conclusion of this study still needs to include more patients for longer follow-up and further investigate the clinical efficacy and safety.

Data availability statement

The original contributions presented in this study are included in this article/Supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of the Second Affiliated Hospital of Air Force Military Medical University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

PY and XL performed the substantial contributions to conception, design, and drafted the manuscript. CW, TL, and HW revised the manuscript critically for important intellectual content and approved the final version to be published. All authors contributed to the article and approved the submitted version.

Acknowledgments

We would like to thank Home for Researchers (www.home-for-researchers.com) for English language editing.

Funding Statement

This work was supported by the Natural Science Foundation of Shaanxi Province (Grant no. 2022JQ-921).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.1059420/full#supplementary-material

Click here for additional data file. (62.1KB, xlsx)
Click here for additional data file. (18.7KB, xlsx)
Click here for additional data file. (49.2KB, xlsx)
Click here for additional data file. (51KB, xlsx)
Click here for additional data file. (21KB, xlsx)
Click here for additional data file. (92.9KB, xlsx)
Click here for additional data file. (12.9KB, xlsx)
Click here for additional data file. (22.4KB, xlsx)
Click here for additional data file. (42.5KB, xlsx)

References

  • 1.Anderson J, Morrow D. Acute myocardial infarction. N Engl J Med. (2017) 376:2053–64. 10.1056/NEJMra1606915 [DOI] [PubMed] [Google Scholar]
  • 2.Damluji A, van Diepen S, Katz J, Menon V, Tamis-Holland J, Bakitas M, et al. Mechanical complications of acute myocardial infarction: a scientific statement from the American heart association. Circulation. (2021) 144:e16–35. 10.1161/CIR.0000000000000985 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Honda S, Asaumi Y, Yamane T, Nagai T, Miyagi T, Noguchi T, et al. Trends in the clinical and pathological characteristics of cardiac rupture in patients with acute myocardial infarction over 35 years. J Am Heart Assoc. (2014) 3:e000984. 10.1161/JAHA.114.000984 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Liu Y, Fan Y, Li J, Chen M, Chen A, Yang D, et al. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice. Biomed Pharmacother. (2021) 133:110824. 10.1016/j.biopha.2020.110824 [DOI] [PubMed] [Google Scholar]
  • 5.Liu X, Xu X, Chu Y, Ren Y, Wang L. Zofenopril versus ramipril in the early phase of acute myocardial infarction with systolic dysfunction: a retrospective study. J Renin Angiotensin Aldosterone Syst. (2020) 21:1470320320946530. 10.1177/1470320320946530 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42:3599–726. [DOI] [PubMed] [Google Scholar]
  • 7.McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the valsartan in acute myocardial infarction trial (VALIANT). J Am Coll Cardiol. (2006) 47:726–33. 10.1016/j.jacc.2005.09.055 [DOI] [PubMed] [Google Scholar]
  • 8.Zaid I, Lang C. Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients. Drugs Today. (2017) 53:545–51. 10.1358/dot.2017.53.10.2722396 [DOI] [PubMed] [Google Scholar]
  • 9.Jackson A, Jhund P, Anand I, Dungen H, Lam C, Lefkowitz M, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. (2021) 42:3741–52. 10.1093/eurheartj/ehab499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Packer M, Anker S, Butler J, Filippatos G, Ferreira J, Pocock S, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. (2021) 42:671–80. 10.1093/eurheartj/ehaa968 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Suzuki K, Claggett B, Minamisawa M, Nochioka K, Mitchell G, Anand I, et al. Pulse pressure, prognosis, and influence of sacubitril/valsartan in heart failure with preserved ejection fraction. Hypertension. (2021) 77:546–56. 10.1161/HYPERTENSIONAHA.120.16277 [DOI] [PubMed] [Google Scholar]
  • 12.Rohde L, Claggett B, Wolsk E, Packer M, Zile M, Swedberg K, et al. Cardiac and noncardiac disease burden and treatment effect of sacubitril/valsartan: insights from a combined PARAGON-HF and PARADIGM-HF analysis. Circ Heart Fail. (2021) 14:e008052. 10.1161/CIRCHEARTFAILURE.120.008052 [DOI] [PubMed] [Google Scholar]
  • 13.Zhao J, Zeng Y, Shen X. Efficacy and safety of early initiation of sacubitril/valsartan in patients after acute myocardial infarction: a meta-analysis. Clin Cardiol. (2021) 44:1354–9. 10.1002/clc.23717 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Xiong B, Nie D, Qian J, Yao Y, Yang G, Rong S, et al. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC Heart Fail. (2021) 8:4852–62. 10.1002/ehf2.13677 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Docherty K, Campbell R, Brooksbank K, Dreisbach J, Forsyth P, Godeseth R, et al. Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation. (2021) 144:199–209. 10.1161/CIRCULATIONAHA.121.054892 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ishii M, Kaikita K, Sato K, Sueta D, Fujisue K, Arima Y, et al. Cardioprotective effects of LCZ696 (sacubitril/valsartan) after experimental acute myocardial infarction. JACC Basic Transl Sci. (2017) 2:655–68. 10.1016/j.jacbts.2017.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Torrado J, Cain C, Mauro A, Romeo F, Ockaili R, Chau V, et al. Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits. J Am Coll Cardiol. (2018) 72:2342–56. 10.1016/j.jacc.2018.07.102 [DOI] [PubMed] [Google Scholar]
  • 18.Cunningham J, Claggett B, O’Meara E, Prescott M, Pfeffer M, Shah S, et al. Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol. (2020) 76:503–14. 10.1016/j.jacc.2020.05.072 [DOI] [PubMed] [Google Scholar]
  • 19.Imran M, Hassan M, Akhtar M, Rahman O, Akhtar M, Najmi A. Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in wistar rats. Clin Exp Hypertens. (2019) 41:62–9. 10.1080/10641963.2018.1441862 [DOI] [PubMed] [Google Scholar]
  • 20.Pfau D, Thorn S, Zhang J, Mikush N, Renaud J, Klein R, et al. Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure. Sci Rep. (2019) 9:5791. 10.1038/s41598-019-42113-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Pfeffer M, Claggett B, Lewis E, Granger C, Kober L, Maggioni A, et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. (2021) 385:1845–55. 10.1056/NEJMoa2104508 [DOI] [PubMed] [Google Scholar]
  • 22.Wang H, Fu X. Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coron Artery Dis. (2021) 32:418–26. 10.1097/MCA.0000000000000932 [DOI] [PubMed] [Google Scholar]
  • 23.Li T, Providencia R, Jiang W, Liu M, Yu L, Gu C, et al. Association of metformin with the mortality and incidence of cardiovascular events in patients with pre-existing cardiovascular diseases. Drugs. (2022) 82:311–22. 10.1007/s40265-021-01665-0 [DOI] [PubMed] [Google Scholar]
  • 24.Gao K, Cao L, Ma W, Gao Y, Luo M, Zhu J, et al. Association between sarcopenia and cardiovascular disease among middle-aged and older adults: findings from the China health and retirement longitudinal study. EClinicalMedicine. (2022) 44:101264. 10.1016/j.eclinm.2021.101264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Li T, Yin Y, Mu N, Wang Y, Liu M, Chen M, et al. Metformin-enhanced cardiac AMP-activated protein kinase/atrogin-1 pathways inhibit charged multivesicular body protein 2B accumulation in ischemia-reperfusion injury. Front Cell Dev Biol. (2020) 8:621509. 10.3389/fcell.2020.621509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Stone G, Selker H, Thiele H, Patel M, Udelson J, Ohman E, et al. Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J Am Coll Cardiol. (2016) 67:1674–83. 10.1016/j.jacc.2016.01.069 [DOI] [PubMed] [Google Scholar]
  • 27.Seropian I, Toldo S, Van Tassell B, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol. (2014) 63:1593–603. 10.1016/j.jacc.2014.01.014 [DOI] [PubMed] [Google Scholar]
  • 28.Zaliaduonyte-Peksiene D, Simonyte S, Lesauskaite V, Vaskelyte J, Gustiene O, Mizariene V, et al. Left ventricular remodelling after acute myocardial infarction: impact of clinical, echocardiographic parameters and polymorphism of angiotensinogen gene. J Renin Angiotensin Aldosterone Syst. (2014) 15:286–93. 10.1177/1470320312471228 [DOI] [PubMed] [Google Scholar]
  • 29.Tarantini G, Napodano M, Gasparetto N, Favaretto E, Marra M, Cacciavillani L, et al. Impact of multivessel coronary artery disease on early ischemic injury, late clinical outcome, and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty. Coron Artery Dis. (2010) 21:78–86. 10.1097/MCA.0b013e328335a074 [DOI] [PubMed] [Google Scholar]
  • 30.Christakopoulos G, Tarar M, Brilakis E. The impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcomes. J Thorac Dis. (2015) 7:1107–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Aplin M, Kyhl K, Bjerre J, Ihlemann N, Greenwood J, Plein S, et al. Cardiac remodelling and function with primary mitral valve insufficiency studied by magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. (2016) 17:863–70. 10.1093/ehjci/jev321 [DOI] [PubMed] [Google Scholar]
  • 32.Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. (2018) 39:119–77. [DOI] [PubMed] [Google Scholar]
  • 33.Collet J, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt D, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. (2021) 42:1289–367. 10.1093/eurheartj/ehaa909 [DOI] [PubMed] [Google Scholar]
  • 34.Kompa A, Lu J, Weller T, Kelly D, Krum H, von Lueder T, et al. Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. Int J Cardiol. (2018) 258:192–8. 10.1016/j.ijcard.2018.01.077 [DOI] [PubMed] [Google Scholar]
  • 35.Jering K, Claggett B, Pfeffer M, Granger C, Kober L, Lewis E, et al. Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. (2021) 23:1040–8. 10.1002/ejhf.2191 [DOI] [PubMed] [Google Scholar]
  • 36.Mann D, Greene S, Givertz M, Vader J, Starling R, Ambrosy A, et al. Sacubitril/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial. JACC Heart Fail. (2020) 8:789–99. 10.1016/j.jchf.2020.05.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lin D, Wang T, Buranakitjaroen P, Chen C, Cheng H, Chia Y, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe. J Clin Hypertens. (2021) 23:556–67. 10.1111/jch.14120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chang H, Feng A, Fong M, Hsueh C, Lai W, Huang K, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. (2019) 74:372–80. 10.1016/j.jjcc.2019.03.010 [DOI] [PubMed] [Google Scholar]
  • 39.Kang D, Park S, Shin S, Hong G, Lee S, Kim M, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation. (2019) 139:1354–65. 10.1161/CIRCULATIONAHA.118.037077 [DOI] [PubMed] [Google Scholar]
  • 40.Packer M, Claggett B, Lefkowitz M, McMurray J, Rouleau J, Solomon S, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. (2018) 6:547–54. 10.1016/S2213-8587(18)30100-1 [DOI] [PubMed] [Google Scholar]
  • 41.Pritchett A, Jacobsen S, Mahoney D, Rodeheffer R, Bailey K, Redfield M. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol. (2003) 41:1036–43. 10.1016/S0735-1097(02)02981-9 [DOI] [PubMed] [Google Scholar]
  • 42.Zhao Y, Yu H, Zhao X, Ma R, Li N, Yu J. The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. (2017) 22:447–57. 10.1177/1074248417693379 [DOI] [PubMed] [Google Scholar]
  • 43.Yandrapalli S, Aronow W, Mondal P, Chabbott D. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Arch Med Sci. (2017) 13:1207–16. 10.5114/aoms.2017.68813 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc. (2019) 8:e012272. 10.1161/JAHA.119.012272 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Zhang Y, Wu Y, Zhang K, Ke Z, Hu P, Jin D. Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Coron Artery Dis. (2021) 32:427–31. 10.1097/MCA.0000000000000955 [DOI] [PubMed] [Google Scholar]
  • 46.Januzzi J, Jr, Prescott M, Butler J, Felker G, Maisel A, McCague K, et al. Association of change in N-terminal Pro-B-Type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. (2019) 322:1085–95. 10.1001/jama.2019.12821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Pascual-Figal D, Wachter R, Senni M, Bao W, Noe A, Schwende H, et al. NT-proBNP response to sacubitril/valsartan in hospitalized heart failure patients with reduced ejection fraction: TRANSITION study. JACC Heart Fail. (2020) 8:822–33. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (62.1KB, xlsx)
Click here for additional data file. (18.7KB, xlsx)
Click here for additional data file. (49.2KB, xlsx)
Click here for additional data file. (51KB, xlsx)
Click here for additional data file. (21KB, xlsx)
Click here for additional data file. (92.9KB, xlsx)
Click here for additional data file. (12.9KB, xlsx)
Click here for additional data file. (22.4KB, xlsx)
Click here for additional data file. (42.5KB, xlsx)

Data Availability Statement

The original contributions presented in this study are included in this article/Supplementary material, further inquiries can be directed to the corresponding authors.

Articles from Frontiers in Cardiovascular Medicine are provided here courtesy of Frontiers Media SA

RESOURCES